Search results for: 'cdmo industry analysi'

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry's value chain. The growing incidence of chronic diseases propels t...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

The Sri Lankan government’s commitment to the healthcare and education sectors is commendable. However, the demographic and epidemiological transformation is urging for reforming the primary healthcare delivery model of the country. Non-communicable diseases are on the rise and account for 85% of deaths in the country. The quality of healthcare ser...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

Natural resource scarcity, the harmful environmental impacts of emissions, and discarded materials in landfills and water bodies are pressing global challenges. The lighting industry significantly contributes to eWaste and pollution, including greenhouse gases and used materials from parts. This challenge warrants adopting circular economy principl...

The space industry is no longer sustained by governmental bodies and aerospace and defense companies. In the modern space race, the private sector is dominating by discovering new opportunities regarding innovations and public-private partnerships. The term “NewSpace” heralds the arrival of private space company ventures. Start-ups, investors, ...

The global space industry has been expanding with the entry of new participants and non-space companies that are extending their roles to cater to both the upstream and the downstream segments. The upstream segment is expanding exponentially and is seeing successful launches by low earth orbit (LEO) satellite constellation operators as well as plan...